Russian Covid vaccine shows encouraging results Early results from trials of a Covid vaccine developed in Russia suggest it could be 92% effective. The data is based on 20 cases of Covid-19 from 16,000 volunteers given the Sputnik V vaccine or a dummy injection. While some scientists welcomed the news, others said the data had been rushed out too early. It comes after Pfizer and BioNTech said their vaccine could prevent 90% of people getting Covid-19, based on a study of 43,500 people. Although the Sputnik data is based on fewer people being vaccinated and fewer cases of Covid developing during the trial, it does confirm promising results from earlier research. The Sputnik V vaccine, developed at the National Research Centre for Epidemiology and Microbiology in Moscow, is currently going through phase III clinical trials in Belarus, UAE, Venezuela and India. So far there are no safety issues, with Russian researchers saying there were "no unexpected adverse events" 21 days after volunteers received their first of two injections.
Just a reminder Germany funded the development of Pfizer's COVID vaccine—not U.S.'s Operation Warp Speed
two Turkish born physicians, married, leading targeted cancer treatment researchers, developed the vaccine. true power couple worth billions and apparently brilliant. proof of concept of RMNA vaccines totally changes vaccine development science.
Just throwing this out there. I have a client who has family who is high level DHS. This person has read the deep level govt reports on the vaccine, the ones the public never sees. There not classified but not for pubic reading. This person told my client to take the vaccine as soon as available, that the research is solid, period. I know this is anecdotal but just passing it on.
I found the following to be an interesting read and hopefully another milestone in the fight against the disease. 'Breakthrough finding' reveals why certain Covid-19 patients die Dr. Megan Ranney has learned a lot about Covid-19 since she began treating patients with the disease in the emergency department in February. But there's one question she still can't answer: What makes some patients so much sicker than others? Advancing age and underlying medical problems explain only part of the phenomenon, said Ranney, who has seen patients of similar age, background and health status follow wildly different trajectories. Full coverage of the coronavirus outbreak "Why does one 40-year-old get really sick and another one not even need to be admitted?" asked Ranney, an associate professor of emergency medicine at Brown University. 'Breakthrough finding' reveals why certain Covid-19 patients die
It is difficult to believe that a vaccine built from a technology that has never been used to bring a vaccine for humans to the point of approval by regulatory bodies can be known to be safe after just 3-6 months of study. I am no anti-vaccine guy. However, while not pretending to be an expert, or even suggest that it is not safe, I am suggesting that anyone who studies vaccines for a living simply cannot swear that after just 6 months a very tiny number test subjects have been injected that we can know that this is safe to take.
Moderna's first read point suggests a 94% efficacy. Link to the story at CNN has been added to update the post.... Moderna's coronavirus vaccine is 94.5% effective, according to company data - CNN
Moderna also showing better than expected thermal stability of their formulation. Also, of the 90 who became ill in the placebo group, 11 developed severe Covid, while ZERO in the vaccine group leading people to speculate that even if you do develop Covid the vaccine lessens the impact on your body. Finally, best news was that the Vaccine group included young 18-25, as well as older 65+ with 1 or more co-morbidities and there were zero reports of adverse affects. COVID-19 tracker: Moderna vaccine nears 95% efficacy in phase 3; Johnson & Johnson kicks off 2-dose shot trial
Roche gearing up to throw their considerable manufacturing capability into producing the Regeneron Monoclonal Anti-body treatment. Regeneron says Roche successfully tested manufacture of COVID-19 drug used on Trump
Lot of good news lately, no a cure, but at home test approved Coronavirus (COVID-19) Update: FDA Authorizes First COVID-19 Test for Self-Testing at Home
Pfizer plans to file for Emergency Use Authorization for its vaccine tomorrow, Friday 11/20, and they plan on shipping within hours of receiving that authorization. COVID-19 tracker: Pfizer to seek U.S. emergency OK Friday as BioNTech eyes room temp-stable formula in 2021: report
UPDATED: Better story I think and a better link: Astrazenneca vaccine candidate 70% at lower dose, about 90% with the full second dose. Expect 200 million doses by the end of 2020. 3rd major COVID-19 vaccine shown to be effective and cheaper
FDA grant Emergency Use Authorization for Regeneron Antibody cocktail. [Covid-19: FDA allows emergency use of antibody drug Regeneron] The drug, developed by Regeneron, will be allowed for use in people who have tested positive for the virus and are at risk of severe illness. Studies suggest the therapy is effective when administered early after diagnosis, the company says. It comes as Covid-19 cases in the country continue to rise. Emergency authorisation by the Food and Drug Administration (FDA) allows use of a treatment while studies are carried out to determine safety and effectiveness.
Nasal spray, consisting of a cholesterol particle that matches the amino acid chain on the Virus Spike that it uses to attach to the human lung cells. The spray particles attach themselves to the amino acid chain on the spike and interferes with the attachment process, thus halting viral replication. The researchers will seek funding from Operation Warp speed to perform human testing.
